3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
5
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Prostate Cancer Patients
1
Prostate Cancer Metastatic
1
Postoperative Cognitive Complications
1
Pharmacokinetics of MDV3100
1
Pain
1
Lung Neoplasms
1
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
belinostat
2
Ifosfamide
2
Filgrastim
2
Doxorubicin
2
enzalutamide
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
Immunotherapy
1
Imatinib Mesylate
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Cyproheptadine
1
Chemotherapy, Adjuvant
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
Midazolam
×
Genitourinary
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled